Literature DB >> 7556674

Peroxynitrite-mediated oxidation of dihydrorhodamine 123 occurs in early stages of endotoxic and hemorrhagic shock and ischemia-reperfusion injury.

C Szabó1, A L Salzman, H Ischiropoulos.   

Abstract

To quantify peroxynitrite production during shock, we measured oxidation of dihydrorhodamine 123 in rats. In endotoxic and hemorrhagic shock and splanchic ischemia-reperfusion, dihydrorhodamine oxidation rapidly increased, which was prevented by inhibition of endothelial nitric oxide (.NO) synthase (ecNOS). Thus, peroxynitrite is already formed at early stages of shock from ecNOS-derived .NO. Overproduction of .NO by the inducible NOS at late shock was not associated with additional increases in dihydrorhodamine oxidation. ecNOS inhibition enhanced dihydrorhodamine oxidation in control rats. These latter findings may be explained by .NO-mediated inhibition of peroxynitrite-induced dihydrorhodamine oxidation, a phenomenon also observed in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556674     DOI: 10.1016/0014-5793(95)00984-h

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  24 in total

1.  Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats.

Authors:  D J Lefer; R Scalia; B Campbell; T Nossuli; R Hayward; M Salamon; J Grayson; A M Lefer
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia.

Authors:  C Szabó; G Haskó; B Zingarelli; Z H Németh; A L Salzman; V Kvetan; S M Pastores; E S Vizi
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

Review 3.  Pathophysiological roles of peroxynitrite in circulatory shock.

Authors:  Csaba Szabó; Katalin Módis
Journal:  Shock       Date:  2010-09       Impact factor: 3.454

4.  Effects of inhibitors of the activity of poly (ADP-ribose) synthetase on the organ injury and dysfunction caused by haemorrhagic shock.

Authors:  M C McDonald; H M Filipe; C Thiemermann
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

5.  Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite.

Authors:  C Szabó; S Cuzzocrea; B Zingarelli; M O'Connor; A L Salzman
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

6.  Protein nitration in cutaneous inflammation in the rat: essential role of inducible nitric oxide synthase and polymorphonuclear leukocytes.

Authors:  S A B Greenacre; F A C Rocha; A Rawlingson; S Meinerikandathevan; R N Poston; E Ruiz; B Halliwell; S D Brain
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

7.  Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats.

Authors:  Meenakshisundaram Thiyagarajan; Chaman Lal Kaul; Shyam Sundar Sharma
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

8.  Effect of S-methylisothiourea in acetaminophen-induced hepatotoxicity in rat.

Authors:  Amar S More; Rashmi R Kumari; Gaurav Gupta; Kandasamy Kathirvel; Milindmitra K Lonare; Rohini S Dhayagude; Dhirendra Kumar; Dinesh Kumar; Anil K Sharma; Surendra K Tandan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-08-11       Impact factor: 3.000

9.  Tyrphostin AG 126 reduces intestinal ischemia-reperfusion injury in the rat.

Authors:  Stefania Marzocco; Emanuela Mazzon; Aldo Pinto; Giuseppina Autore; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-17       Impact factor: 3.000

10.  Imbalance between levels of nitrogen oxides and peroxynitrite inhibitory activity in chronic obstructive pulmonary disease.

Authors:  H Kanazawa; S Shiraishi; K Hirata; J Yoshikawa
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.